<DOC>
	<DOCNO>NCT01676701</DOCNO>
	<brief_summary>The purpose study evaluate serum concentration tabalumab administration use either prefilled syringe auto-injector initial load dose 12 week treatment . Treatment period follow 40 week optional safety extension .</brief_summary>
	<brief_title>Evaluation Tabalumab Using Auto-Injector Prefilled Syringe Participants With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Ambulatory male females â‰¥18 year age Diagnosis adultonset RA Active RA ( least 8/68 tender least 8/66 swollen joint ) Screening Creactive protein &gt; 1.2 time upper limit normal ( ULN ) screen erythrocyte sedimentation rate ( ESR ) &gt; 28 millimeter per hour ( mm/hr ) Documented history , current , positive rheumatoid factor ( RF ) and/or anticyclic citrullinated peptide antibody ( antiCCP Ab ) test Regular use methotrexate ( MTX ) least 12 week stable dose ( 10 25 mg/week ) least 8 week prior baseline American College Rheumatology ( ACR ) functional class I , II , III Able willing inject tabalumab ( assistant inject tabalumab ) able willing complete study procedure Able willing blood drawn pharmacokinetic ( PK ) sample Use oral corticosteroid average daily dose &gt; 10 mg/day prednisone equivalent within 6 week prior baseline Injection parenteral ( include intraarticular ) corticosteroid within 6 week baseline Have previously discontinue treatment biologic diseasemodifying antirheumatic drug ( DMARD ) novel drug interrupt cytokine signal ( eg , Janus kinase [ JAK ] inhibitor ) due insufficient efficacy Participants discontinue biologic DMARDS reason efficacy exclude must do prior baseline Participants discontinue JAK inhibitor lack efficacy Participants discontinue JAK inhibitor reason efficacy exclude , must do prior baseline 21 day Previous severe reaction biologic therapy , opinion Investigator , would pose unacceptable risk participant participate study Have inadequate response treatment 3 follow DMARDs prescribe alone combination approve dos minimum 90 day : leflunomide , azathioprine , cyclosporine , and/or sulfasalazine Use DMARDs ( eg , gold salt , cyclosporin , azathioprine , immunosuppressive ) MTX , hydroxychloroquine , chloroquine , sulfasalazine , use JAK inhibitor 8 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>